JP2015514756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514756A5 JP2015514756A5 JP2015506952A JP2015506952A JP2015514756A5 JP 2015514756 A5 JP2015514756 A5 JP 2015514756A5 JP 2015506952 A JP2015506952 A JP 2015506952A JP 2015506952 A JP2015506952 A JP 2015506952A JP 2015514756 A5 JP2015514756 A5 JP 2015514756A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- inhibitor
- glucose
- composition
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical group C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 9
- 229960003834 dapagliflozin Drugs 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims description 8
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 claims description 7
- 229950011595 glufosfamide Drugs 0.000 claims description 7
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 4
- 108091052347 Glucose transporter family Proteins 0.000 claims description 4
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims description 4
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960001713 canagliflozin Drugs 0.000 claims description 4
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 4
- 229960003345 empagliflozin Drugs 0.000 claims description 4
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims description 4
- 229950000991 ipragliflozin Drugs 0.000 claims description 4
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 229940126844 remogliflozin Drugs 0.000 claims description 4
- 229940126842 sergliflozin Drugs 0.000 claims description 4
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 claims description 4
- 229950006667 tofogliflozin Drugs 0.000 claims description 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 102000058058 Glucose Transporter Type 2 Human genes 0.000 claims description 2
- 108091006299 SLC2A2 Proteins 0.000 claims description 2
- 108091006269 SLC5A2 Proteins 0.000 claims description 2
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261687114P | 2012-04-19 | 2012-04-19 | |
| US61/687,114 | 2012-04-19 | ||
| PCT/US2012/053275 WO2013158143A1 (en) | 2012-04-19 | 2012-08-31 | Glufosfamide combination therapies for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018025930A Division JP2018087228A (ja) | 2012-04-19 | 2018-02-16 | がんのためのグルフォスファミド組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514756A JP2015514756A (ja) | 2015-05-21 |
| JP2015514756A5 true JP2015514756A5 (enExample) | 2015-10-15 |
Family
ID=49380659
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506952A Withdrawn JP2015514756A (ja) | 2012-04-19 | 2012-08-31 | がんのためのグルフォスファミド組み合わせ療法 |
| JP2018025930A Withdrawn JP2018087228A (ja) | 2012-04-19 | 2018-02-16 | がんのためのグルフォスファミド組み合わせ療法 |
| JP2020005694A Pending JP2020055884A (ja) | 2012-04-19 | 2020-01-17 | がんのためのグルフォスファミド組み合わせ療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018025930A Withdrawn JP2018087228A (ja) | 2012-04-19 | 2018-02-16 | がんのためのグルフォスファミド組み合わせ療法 |
| JP2020005694A Pending JP2020055884A (ja) | 2012-04-19 | 2020-01-17 | がんのためのグルフォスファミド組み合わせ療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130281386A1 (enExample) |
| EP (1) | EP2846638A4 (enExample) |
| JP (3) | JP2015514756A (enExample) |
| CN (1) | CN104270944A (enExample) |
| CA (1) | CA2870138A1 (enExample) |
| HK (1) | HK1207796A1 (enExample) |
| WO (1) | WO2013158143A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134486A1 (en) * | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Use of canagliflozin and derivatives thereof in the treatment of cancer |
| CN105030798B (zh) * | 2015-06-24 | 2017-11-24 | 李宏 | 一种抗肿瘤的药物组合物及其制备方法和应用 |
| CA3031979A1 (en) * | 2016-08-01 | 2018-02-08 | IC-MedTech Corp. | Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer |
| CN110248664B (zh) * | 2017-11-28 | 2023-03-03 | 深圳艾欣达伟医药科技有限公司 | 葡磷酰胺的抗癌医药用途 |
| JP7414230B2 (ja) * | 2018-11-09 | 2024-01-16 | 国立大学法人 琉球大学 | 抗血液悪性腫瘍薬 |
| JP2022521010A (ja) * | 2019-02-21 | 2022-04-04 | イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド | 薬物誘導性腎毒性を減少させるための方法 |
| CN110038009B (zh) | 2019-05-13 | 2021-01-08 | 浙江大学 | 卡格列净在制备抗肿瘤药物中的应用 |
| KR102437311B1 (ko) * | 2019-12-03 | 2022-09-15 | 주식회사 하임네이처 | Ndpk 활성제 및 sglt-2 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR20210084919A (ko) * | 2019-12-30 | 2021-07-08 | 주식회사 하임바이오 | Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
| IL300847A (en) * | 2020-08-26 | 2023-04-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Combined treatment to reduce DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1289077C (en) * | 1984-08-13 | 1991-09-17 | Harry H. Leveen | Treatment of cancer with phlorizin and its derivatives |
| DE19806803A1 (de) * | 1998-02-18 | 1999-11-25 | Hermann Koepsell | Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen |
| AU2003230750A1 (en) * | 2002-03-29 | 2003-10-13 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| KR20050111752A (ko) * | 2003-03-07 | 2005-11-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법 |
| WO2006122227A1 (en) * | 2005-05-11 | 2006-11-16 | Threshold Pharmaceuticals, Inc. | Glufosfamide combination therapy |
| WO2008124691A1 (en) * | 2007-04-05 | 2008-10-16 | Threshold Pharmaceuticals, Inc. | Glufosfamide combination therapy |
| WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
-
2012
- 2012-08-30 US US13/599,684 patent/US20130281386A1/en not_active Abandoned
- 2012-08-31 CA CA2870138A patent/CA2870138A1/en not_active Abandoned
- 2012-08-31 JP JP2015506952A patent/JP2015514756A/ja not_active Withdrawn
- 2012-08-31 EP EP12874672.4A patent/EP2846638A4/en not_active Withdrawn
- 2012-08-31 CN CN201280072538.2A patent/CN104270944A/zh active Pending
- 2012-08-31 WO PCT/US2012/053275 patent/WO2013158143A1/en not_active Ceased
- 2012-08-31 HK HK15108524.1A patent/HK1207796A1/xx unknown
-
2018
- 2018-02-16 JP JP2018025930A patent/JP2018087228A/ja not_active Withdrawn
-
2020
- 2020-01-17 JP JP2020005694A patent/JP2020055884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514756A5 (enExample) | ||
| JP6787789B2 (ja) | 詰め替え可能な薬物送達デバイスおよびその使用方法 | |
| WO2008081927A1 (ja) | 抗癌剤の併用による癌治療方法 | |
| IL311603A (en) | Binding molecules that regulate biological activity expressed by a cell | |
| JP2013503174A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| WO2009120697A3 (en) | Method and compositions for treatment of cancer | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| WO2017044983A1 (en) | Bioorthogonal compositions | |
| JP2006504723A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| JP2021505661A5 (enExample) | ||
| WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
| CA2546730A1 (en) | A method for the treatment of malignant diseases by inhibiting nucleolin | |
| SE0402025D0 (sv) | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | |
| JP2008502584A5 (enExample) | ||
| JP2010180210A5 (enExample) | ||
| WO2005072061A3 (en) | Conjugates for cancer therapy and diagnosis | |
| JP2010523696A5 (enExample) | ||
| EP2949344A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
| JP2017514800A5 (enExample) | ||
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| JP2006500346A5 (enExample) | ||
| JP2019506862A5 (enExample) |